NANOBIOTIX Extends its Financial Horizon until mid-2026

Nanobiotix announces the amendment of a key agreement with Janssen Pharmaceutica NV, part of Johnson & Johnson. This agreement, for NBTXR3, includes Johnson & Johnson covering costs related to the NANORAY-312 study. This allows Nanobiotix to extend its financial visibility until mid-2026, while reducing its operational costs.

The contract, initially valued at $2.7 billion, has now been adjusted to approximately $2.6 billion. However, Nanobiotix maintains its ability to receive potential milestone payments, including $1.77 billion for development, regulatory, and sales aspects.

Bart Van Rhijn, Chief Financial Officer, emphasizes that this financial approach guarantees continuity while ensuring operational alignment and the potential for significant future revenues.